NCT02152995 2026-04-13
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT03914300 2026-04-13
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05575440 2026-02-27
Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer
Mayo Clinic
Recruiting
NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT06959641 2025-06-11
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Northwestern University
Phase 2 Recruiting
NCT02178345 2021-12-08
Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Completed
NCT00085293 2018-11-29
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
National Cancer Institute (NCI)
Phase 2 Completed
NCT00729157 2017-03-15
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098813 2014-05-28
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
National Cancer Institute (NCI)
Phase 2 Completed
NCT00095693 2014-01-16
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated